How much revenue does Beijing Tiantan Biological Products make?

Beijing Tiantan Biological Products reported 6.17 billion CNY in revenue for fiscal year 2025, up 2.3% from 6.03 billion CNY in fiscal year 2024. In Q1 2026 revenue was 1.14 billion CNY.

Where does Beijing Tiantan Biological Products make most of its revenue?

China: 100% of revenue by region in fiscal year 2025, followed by Overseas (under 1%).

What companies are similar to Beijing Tiantan Biological Products?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ), Livzon Pharmaceutical Group Inc. (000513.SZ), Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS), Hualan Biological Engineering Inc. (002007.SZ).

Beijing Tiantan Biological Products Co., Ltd. (600161.SS) Stock

About Beijing Tiantan Biological Products Co., Ltd.

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationally. Its products include human serum albumin; intravenous human immunoglobulin; rabies immunoglobulin; tetanus immunoglobulin; hepatitis B immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immuno...

At a glance

Beijing Tiantan Biological Products reported revenue of 6.17 billion CNY for fiscal year 2025, up 2.3% from fiscal year 2024, and net income of 1.09 billion CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 1.14 billion CNY, down 13.4% from a year before. China was its largest region in fiscal year 2025, with 100% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.